Selinexor and Chemotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
Status:
Completed
Trial end date:
2018-03-06
Target enrollment:
Participant gender:
Summary
This phase I trial studies the side effects and best dose of selinexor when given together
with etoposide with or without mitoxantrone hydrochloride and cytarabine in treating patients
with acute myeloid leukemia that has returned (relapsed) or has not responded to treatment
(refractory). Selinexor may help stop the growth of tumor cells by blocking an enzyme needed
for cancer cell growth. Drugs used in chemotherapy, such as etoposide, mitoxantrone
hydrochloride, and cytarabine, work in different ways to stop the growth of cancer cells,
either by killing the cells, by stopping them from dividing, or by stopping them from
spreading. Giving chemotherapy together with selinexor work better in treating relapsed or
refractory acute myeloid leukemia.